Dicot Pharma is a Uppsala-based pharmaceutical company collaborating with leading partners and renowned experts worldwide to develop the next generation of erectile dysfunction treatments. The goal is for the drug candidate LIB-01 to provide better treatment for erectile dysfunction and premature ejaculation compared to existing drugs.
Our clinical studies with LIB-01 focus on erectile dysfunction, and we are currently in Phase 2. Results from completed clinical studies show that LIB-01 improves erectile function, and that the effect sustains during eight weeks — and that the candidate demonstrates an excellent safety profile.
New research findings indicate that the substance may also influence factors related to metabolic diseases. A preclinical study is now underway in parallel with the development of the potency drug candidate.
An intensive IP-strategy has resulted in seven patent families and granted patents extending until 2042.
Dicot Pharma’s business model involves evaluating financial and industrial partnerships during the clinical development phase to bring LIB-01 to commercialization.
